Higher vigilance needed to diagnose and treat MDD
| dc.contributor.author | Du Plessis, Ilse | |
| dc.date.accessioned | 2016-03-08T06:08:30Z | |
| dc.date.available | 2016-03-08T06:08:30Z | |
| dc.date.issued | 2015-08 | |
| dc.description.abstract | Selective serotonin reuptake inhibitors (SSRIs) became the first line of treatment of depressive disorders (MDD) during the eighties and has kept its place in the arsenal of options to treat this common disease. MDD accounts for 4,4% of the total overall global disease burden. | en_ZA |
| dc.description.librarian | am2015 | en_ZA |
| dc.description.uri | http://www.specialistforum.co.za | en_ZA |
| dc.identifier.citation | Du Plessis, I 2015, 'Higher vigilance needed to diagnose and treat MDDs', Specialist Forum, vol. 15, no. 7, pp. 12. | en_ZA |
| dc.identifier.issn | 2218-8282 | |
| dc.identifier.uri | http://hdl.handle.net/2263/51711 | |
| dc.language.iso | en | en_ZA |
| dc.publisher | New Media Publishing | en_ZA |
| dc.rights | .© The Specialist Forum | en_ZA |
| dc.subject | Treatment | en_ZA |
| dc.subject | Disease | en_ZA |
| dc.subject | Major depressive disorder (MDD) | en_ZA |
| dc.subject | Selective serotonin reuptake inhibitors (SSRIs) | en_ZA |
| dc.title | Higher vigilance needed to diagnose and treat MDD | en_ZA |
| dc.type | Article | en_ZA |